Subscribe to Newsletter
Business & Profession Business and Innovation

The Top 5 Lessons from Ophthalmology Futures 2014

#1. There’s no consensus on the best way to invest in innovation

Some, like Ralf Kuschnereit from Carl Zeiss Meditec, believe that you need a balanced research and development portfolio. “Bets” can be small and quick (like improvements to a device) or long-term and big – for something truly disruptive. Calvin Roberts (Bausch + Lomb): “Mid-sized companies need to be agile and clever.“ He also said, that you should “balance your portfolio by risk, rather than by speed.” Murthy Simhambhatla’s (Abbott Medical Optics) view was that “Things have changed, now there’s no reward for incremental innovation.”

#2. Femtosecond lasers are almost certainly the future of cataract surgery

From the surgeon’s perspective, Sheraz Daya (Centre for Sight) stated: “Once you go femto for rhexis, you don’t go back – as you can lose the feel of the manual rhexis if you’re not careful.” Julian Stevens (Moorfields) viewed femtosecond lasers as “pretty good”, with a great benefit being the ability to do intrastromal incisions. Patients perceive lasers as “good”, according to Allan Crandall (Moran Eye Center) and that “US advertising drives patients to clinics with femtosecond lasers.”

#3. Reimbursement is the issue that needs to be overcome before femtosecond-laser assisted cataract surgery becomes widespread.

In essence, no play, if insurers won’t pay. Matteo Piovella (President of the Italian Ophthalmological Society) explained that “Femto reimbursement is impossible in my country” – politics. Béatrice Cochener (University Hospital, Brest) empathized: the French Ministry of Health trial looks like “it will be hard to demonstrate a robust health-economic benefit of femto-cataract surgery.” Soon-Phail Chee (SNEC): put it bluntly: “It’s simple – you need to show femto is safer than manual rhexis – and better – before insurers will pay.”

#4. Patients age – you’re fixing the problem as it is today, not as it will be tomorrow. Manage patients’ expectations!

Sheraz Daya: “Current interventions are short-term. But the cornea changes, as do the effect of LRIs. Perhaps we should be thinking of the longer term?” Julian Stevens noted one aspect of presbyopia treatment: “Time passes. People get older. They come back!”

#5. Gene and stem cell therapy are set to transform the outcomes of patients with ophthalmic disease... sooner rather than later.

Majlinda Lako (Newcastle University) looks past the technical aspects: “Growing stem cells – those issues have been overcome. The regulatory hurdles are the next challenge.” Interestingly, the biggest advocates of this kind of research aren’t necessarily the charities: Sir Peng Khaw (Moorfields) noted that “Patients are often the biggest advocates of getting stem/gene therapy trials funded.”

The metrics of success are hard to identify with gene and stem cell therapy – what outcomes should be used? Keith Martin (Cambridge University) explained that the overall impact of the therapy on peoples’ lives is what matters. “Many funders now want quality of life measures as efficacy outcomes in their clinical trials of gene and stem cell therapies.” Finally, Peng Khaw raised the stakes: “Stem cell regenerative therapy is as disruptive and game-changing as anything Apple or Google do.”

www.ophthalmology-futures.com

Receive content, products, events as well as relevant industry updates from The Ophthalmologist and its sponsors.

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

About the Author
Mark Hillen

I spent seven years as a medical writer, writing primary and review manuscripts, congress presentations and marketing materials for numerous – and mostly German – pharmaceutical companies. Prior to my adventures in medical communications, I was a Wellcome Trust PhD student at the University of Edinburgh.

Related Product Profile
Uncover the Unique DNA of SPECTRALIS®

| Contributed by Heidelberg Engineering

Product Profiles

Access our product directory to see the latest products and services from our industry partners

Here
Most Popular
Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine

Register

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: